Arcutis Biotherapeutics Q4 2022 Earnings Report $13.09 -0.33 (-2.44%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Arcutis Biotherapeutics EPS ResultsActual EPS-$1.18Consensus EPS -$1.37Beat/MissBeat by +$0.19One Year Ago EPSN/AArcutis Biotherapeutics Revenue ResultsActual Revenue$2.96 millionExpected Revenue$2.84 millionBeat/MissBeat by +$120.00 thousandYoY Revenue GrowthN/AArcutis Biotherapeutics Announcement DetailsQuarterQ4 2022Date2/28/2023TimeN/AARQT Upcoming EarningsArcutis Biotherapeutics will be holding an earnings conference call on Tuesday, February 25 at 4:30 PM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesSlide DeckPress ReleaseARQT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Arcutis Biotherapeutics Earnings HeadlinesArcutis to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 18 at 4:35 PM | globenewswire.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by BrokeragesFebruary 15, 2025 | americanbankingnews.comNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long run … that's a good thing.February 21, 2025 | Weiss Ratings (Ad)Arcutis Biotherapeutics Becomes Oversold (ARQT)February 13, 2025 | nasdaq.comArcutis Biotherapeutics jumps amid takeover speculationFebruary 12, 2025 | msn.comArcutis Biotherapeutics rumor highlighted in Betaville alertFebruary 12, 2025 | markets.businessinsider.comSee More Arcutis Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcutis Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your email. Email Address About Arcutis BiotherapeuticsArcutis Biotherapeutics (NASDAQ:ARQT), a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.View Arcutis Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
